<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933007</url>
  </required_header>
  <id_info>
    <org_study_id>P170409J</org_study_id>
    <secondary_id>2018-002542-37</secondary_id>
    <nct_id>NCT03933007</nct_id>
  </id_info>
  <brief_title>Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare</brief_title>
  <acronym>COMpARE</acronym>
  <official_title>Comparison of Maximum Blood Concentrations of Colchicine Between Responders and Non-responders to Colchicine Treatment During Gout Flare</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gout, secondary to sodium urate crystal deposition, is responsible of recurrent inflammatory&#xD;
      painful flares. Efficacy of colchicine which is the first line drug for the treatment and&#xD;
      prophylaxis of gout flare varies and only half of treated patients experience good response.&#xD;
      This study aims to optimize colchicine prescription for the treatment and prophylaxis of gout&#xD;
      flare.&#xD;
&#xD;
      Current data suggest that efficiency of colchicine relies on its maximum blood concentration&#xD;
      (Cmax).&#xD;
&#xD;
      In this study, the investigators hypothesize that responders to colchicine treatment have&#xD;
      higher colchicine Cmax than non-responder patients following the recommended dose regimen (1&#xD;
      mg then 0.5 mg 1 hour later).&#xD;
&#xD;
      The individual pharmacokinetics (PK) of colchicine remains poorly investigated while the&#xD;
      assessment of individual drug metabolisms can be performed.&#xD;
&#xD;
      The hypothesis of this study stands that several factors contribute to the variability of&#xD;
      colchicine Cmax. The analysis of individual PK profile and a well-characterized metabolism of&#xD;
      colchicine will permit a personalized treatment regimen for the treatment and prophylaxis of&#xD;
      gout flares.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gout flare is driven by interleukin (IL)-1β production and can be treated by colchicine,&#xD;
      NSAID, corticoid or IL-1β blockers (PMID 27457514).&#xD;
&#xD;
      Colchicine is an alkaloid compound that disrupts cytoskeletal functions through inhibition of&#xD;
      microtubule polymerization and consequently interferes with the intracellular assembly of the&#xD;
      inflammasome NLRP3 complex that mediates activation of IL-1β (PMID 16407889).&#xD;
&#xD;
      Efficacy of colchicine treatment in gout flare varies between 37.5 and 64% (PMID 3314832;&#xD;
      20131255). Previous study suggests that colchicine efficiency relies on its blood maximum&#xD;
      concentration (Cmax) (PMID 20131255). However this hypothesis needs to be confirmed.&#xD;
&#xD;
      The hypothesis of this study stands that colchicine Cmax varies with individual colchicine&#xD;
      pharmacokinetics and that this individual variation may explain the variation response of&#xD;
      colchicine treatment.&#xD;
&#xD;
      Absorption of orally administrated colchicine varies between 24 et 88% with an average of&#xD;
      45%. Thus, following oral administration of 1.8 mg colchicine over 1 hour to healthy young&#xD;
      adults, under fasting condition, the colchicine Cmax (mean 6.2 ng/ml) is reached within a&#xD;
      median of 1.8 hours (range 1.0-2.5) (PMID 20131255).&#xD;
&#xD;
      Colchicine is demethylated to two metabolites, 2-O-demethylcolchicine and&#xD;
      3-O-demethylcolchicine (2- and 3-DMC, respectively). In vitro studies have shown that hepatic&#xD;
      cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of colchicine to 2- and 3-DMC.&#xD;
      Colchicine is also a substrate of liver and intestinal P-glycoprotein (P-gp) transporter.&#xD;
&#xD;
      Colchicine is eliminated in urine and stools. 40-65% of orally administrated colchicine is&#xD;
      recovered unchanged in urine. Enterohepatic recirculation and biliary excretion account for&#xD;
      around 50% of colchicine elimination. The mean half-live elimination is 20 to 40 hours.&#xD;
&#xD;
      Thus, blood concentration of colchicine depends on kidney and hepatic functions, intestinal&#xD;
      absorption and secretion, the presence of drug-drug interactions and individual&#xD;
      characteristics of CYP3A4 and P-gp activities (PMID 21480191).&#xD;
&#xD;
      The individual CYP3A4 and P-gp activities can be assessed with specific probe and/or&#xD;
      substrate of these proteins in the so-called phenotyping assay. Thus, using micro dose of&#xD;
      midazolam and fexofenadine the activity of CYP3A4 and P-gp, respectively, can be determined&#xD;
      and subsequently the individual pharmacokinetic profile of colchicine characterized (PMID&#xD;
      24722393).&#xD;
&#xD;
      CYP3A4 activity is given by the ratio of hydroxy-midazolam/midazolam assessed 2 hours after&#xD;
      an oral administration of 1 mg midazolam (PMID 24722393).&#xD;
&#xD;
      P-gp activity is given by the area under the curve (AUC) of a short kinetic that measures&#xD;
      fexofenadine concentrations at 2, 3 and 6 hours after its oral administration of 120 mg (PMID&#xD;
      24722393).&#xD;
&#xD;
      These CYP3A4 and P-gp activities will be correlated with blood colchicine concentrations&#xD;
      determined at different time points after an oral administration of 1.5 mg over 1 hour under&#xD;
      fasting condition.&#xD;
&#xD;
      The CYP3A4 and P-gp phenotyping will be proposed to all gouty patients who experienced gout&#xD;
      flare and who fulfilled the inclusion and exclusion criteria.&#xD;
&#xD;
      Participants will have 3 visits :&#xD;
&#xD;
        -  V0: inclusion visit of patients who had untreated gout flare. Signed consent to the&#xD;
           study will be collected and blood analysis performed. A blood collection and biobank of&#xD;
           serum will be done using the blood harvested for gout care. Colchicine will be initiated&#xD;
           at 1.5 mg over 1 hour (1 mg + 0.5 mg)&#xD;
&#xD;
        -  V1: treatment efficiency will be assessed 48 h after V0 using Visual Analogue Scale&#xD;
           (VAS) (0-100) pain measurement. Patients who will have an improvement of VAS more than&#xD;
           50% of baseline VAS will be considered as responders to colchicine. In contrast an&#xD;
           improvement less than 50% of baseline VAS will be considered as non-responders. Gout&#xD;
           flare treatment will be adapted according to patient response. Colchicine treatment will&#xD;
           be stopped after gout flare resolution&#xD;
&#xD;
        -  V2: this visit will be appointed 1 month after V1 (far enough after resolution of gout&#xD;
           flare). During this visit, the CYP3A4 and P-gp phenotyping will be performed. Patients&#xD;
           will receive colchicine (1.5 mg over 1 hour) and midazolam (1 mg) and fexofenadine (120&#xD;
           mg) orally. A kinetic of blood samples will be harvested with a total of 8 time points&#xD;
           from T0 prior to drug administration to T6 6 hour post-drug administration. At the end&#xD;
           of the phenotyping kinetic, urate-lowering therapy will be introduced according to usual&#xD;
           care and dosage. This visit is the last visit of the protocol and patients will be&#xD;
           followed-up as usual care.&#xD;
&#xD;
      Plasma concentrations of colchicine, midazolam, hydroxymidazolam and fexofenadine will be&#xD;
      quantified by liquid chromatography-tandem mass spectrometry (PMID 24295116).&#xD;
&#xD;
      Plasma concentrations of colchicine will then correlate to CYP3A4 and P-gp activities&#xD;
      estimated by midazolam and fexofenadine metabolism, respectively.&#xD;
&#xD;
      The phenotyping will be performed in 34 colchicine responder and 34 colchicine non-responder&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Actual">October 10, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>all participants will perform the pharmacokinetic study and take colchicine 1 mg + 0.5 mg 1 hour later, midazolam 1 mg and fexofenadine 120 mg.&#xD;
A pharmacokinetic study is an interventional study with only one arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>all participants will perform the pharmacokinetic study and take colchicine 1 mg + 0.5 mg 1 hour later, midazolam 1 mg and fexofenadine 120 mg.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration of colchicine</measure>
    <time_frame>From drug administration to 6 hour post-drug administration</time_frame>
    <description>Maximum plasma concentration of colchicine in responders and non-responders to colchicine treatment for gout flare during pharmacokinetic study performed 1 month after flare resolution and before initiation of urate-lowering therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>From drug administration to 6 hour post-drug administration</time_frame>
    <description>pharmacokinetic parameter of absorption of colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time needed to reach Cmax [Tmax ]</measure>
    <time_frame>From drug administration to 6 hour post-drug administration</time_frame>
    <description>pharmacokinetic parameter of absorption of colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption rate constant [Ka]</measure>
    <time_frame>From drug administration to 6 hour post-drug administration</time_frame>
    <description>pharmacokinetic parameter of absorption of colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution [Vd]</measure>
    <time_frame>From drug administration to 6 hour post-drug administration</time_frame>
    <description>pharmacokinetic parameter of distribution of colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve [AUC]</measure>
    <time_frame>From drug administration to 6 hour post-drug administration</time_frame>
    <description>pharmacokinetic parameter of distribution of colchicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>From drug administration to 6 hour post-drug administration</time_frame>
    <description>pharmacokinetic parameter of elimination of colchicine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Gout Flare</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetic study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>all participants will undergo pharmacokinetic study and take colchicine (1.5 mg over 1 hour), midazolam (1 mg) and fexofenadine (120 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine,</intervention_name>
    <description>the day of phenotyping assay&#xD;
Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)</description>
    <arm_group_label>Pharmacokinetic study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam,</intervention_name>
    <description>Midazolam 1 mg</description>
    <arm_group_label>Pharmacokinetic study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fexofenadine</intervention_name>
    <description>Fexofenadine 120 mg</description>
    <arm_group_label>Pharmacokinetic study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients (&gt; 18 years old) with gout flare defined by following items :&#xD;
&#xD;
          -  Identification of sodium urate crystals in synovial fluid analysis&#xD;
&#xD;
          -  Or gout flare diagnosis according to Nijmegen criteria (score &gt; 8/13)&#xD;
&#xD;
               -  Man (2 pts)&#xD;
&#xD;
               -  History of flare (2 pts)&#xD;
&#xD;
               -  Flare involving first metatarsophalangeal joint (2.5 pts)&#xD;
&#xD;
               -  Maximum of flare within 24h (0.5pt),&#xD;
&#xD;
               -  Redness (1 pt),&#xD;
&#xD;
               -  History of hypertension or cardiovascular diseases (1.5 pts),&#xD;
&#xD;
               -  Serum urate level &gt; 360 µmol/l during flare (3.5 pts)&#xD;
&#xD;
          -  Duration of flare &lt; 48 h&#xD;
&#xD;
          -  Monoarticular involvement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to colchicine, fexofenadine, benzodiazepine or the excipients of&#xD;
             these drugs&#xD;
&#xD;
          -  Contra-indication to colchicine : chronic kidney disease stage 4-5, severe hepatic&#xD;
             impairment, treatment by macrolide antibiotics&#xD;
&#xD;
          -  Used of pain-killers other than acetaminophen&#xD;
&#xD;
          -  Involvement in another clinical trial with drug administration&#xD;
&#xD;
          -  Illiteracy&#xD;
&#xD;
          -  Pregnant woman or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hang-Korng EA, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP - Groupe hospitalier Lariboisière Fernand Widal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hang-Korng EA, PhD, MD</last_name>
    <phone>33 1 49 95 88 25</phone>
    <email>hang-korng.ea@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lariboisière-Service de Rhumatolologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hang-Korng EA, PhD</last_name>
      <phone>01 49 95 88 25</phone>
      <email>hang-korng.ea@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hang-Korng EA, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Arthritis, Gouty</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

